Search

Your search keyword '"Lombardo, Maurizio"' showing total 29 results
Start Over Author "Lombardo, Maurizio"
29 results on '"Lombardo, Maurizio"'

1. The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086)

Author

Tropea, Saveria, Del Fiore, Paolo, Maurichi, Andrea, Patuzzo, Roberto, Santinami, Mario, Ribero, Simone, Quaglino, Pietro, Caliendo, Virginia, Borgognoni, Lorenzo, Sestini, Serena, Giudice, Giuseppe, Nacchiero, Eleonora, Caracò, Corrado, Cordova, Adriana, Solari, Nicola, Piazzalunga, Dario, Tauceri, Francesca, Carcoforo, Paolo, Lombardo, Maurizio, Cavallari, Sara, and Mocellin, Simone

Published
2022
Full Text
View/download PDF

2. The clinical spectrum of COVID-19–associated cutaneous manifestations: An Italian multicenter study of 200 adult patients

Author

Marzano, Angelo Valerio, Genovese, Giovanni, Moltrasio, Chiara, Gaspari, Valeria, Vezzoli, Pamela, Maione, Vincenzo, Misciali, Cosimo, Sena, Paolo, Patrizi, Annalisa, Offidani, Annamaria, Quaglino, Pietro, Arco, Renato, Caproni, Marzia, Rovesti, Miriam, Bordin, Giorgio, Recalcati, Sebastiano, Potenza, Concetta, Guarneri, Claudio, Fabbrocini, Gabriella, Tomasini, Carlo, Sorci, Mariarita, Lombardo, Maurizio, Gisondi, Paolo, Conti, Andrea, Casazza, Giovanni, Peris, Ketty, Calzavara-Pinton, Piergiacomo, and Berti, Emilio

Published
2021
Full Text
View/download PDF

3. Patients Withdrawing Dupilumab Monotherapy for COVID-19–Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iris, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, and Peris, Ketty

Published
2021
Full Text
View/download PDF

4. Patients Withdrawing Dupilumab Monotherapy for COVID-19–Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iris, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, and Peris, Ketty

Published
2022
Full Text
View/download PDF

5. Preliminary analysis of the melanoma multimedia educational program for general practitioners on behalf of the Italian Melanoma Intergroup.

Author

Zamagni, Federica, Falcini, Fabio, Magi, Serena, Bucchi, Lauro, Mancini, Silvia, Vattiato, Rosa, Crocetti, Emanuele, Falcinelli, Stefano, Feliciani, Claudio, Lombardo, Maurizio, Melandri, Davide, Pizzichetta, Maria Antonietta, Re, Patrizia, Ricci, Francesco, Satta, Rosanna Rita, Gandini, Sara, and Stanganelli, Ignazio

Subjects
NEVUS, MELANOMA diagnosis, ONLINE education, GENERAL practitioners, DISEASE management
Abstract

According to the National Oncological Plan 2023-2027 on the importance of multidisciplinary and interactive e-learning training, the Italian Melanoma Intergroup (IMI) has developed MelaMEd (Melanoma Multimedia Education), a national project for general practitioners (GPs) on the prevention and detection of cutaneous melanoma through an online platform and an online course. MelaMEd enables participants to i) recognize skin lesions that require specialist dermatological assessment, ii) select patients at high risk of melanoma and iii) be informed of the diagnosis and treatment pathway of patients with melanoma. A free online platform and online course were developed and launched in June 2022. Before starting the course, enrolled participants fill out a pre-training questionnaire concerning the basic knowledge of the disease and the recognition and management of suspicious lesions. After the course, participants will fill out the same questionnaire again. The online course will end in December 2023. Here we present a preliminary analysis of the pre-training results (January 2023-July 2023). The data have been analyzed descriptively. So far, five healthcare centers have participated in the project for a total of 1320 participants. Of these, 298 compiled the pre-training questionnaire. Forty-seven percent of them were aged <40 years. Respondents were almost divided between GPs (47%) and resident GPs (48%). Among the theoretical questions, the ABCDE rule and ugly duckling sign are well known (96% and 91% of correct answers, respectively), but a lower percentage (68%) of respondents knows the EFG rule for the recognition of nodular melanomas and the statement of Breslow thickness (29%). Regarding the series of clinical images of pigmented skin lesions and their management, the percentages rate of accuracy varied from 33% to 87%: melanoma (5 cases) ranges from 36% to 71%, melanocytic nevi (3 cases) from 33% to 84%, whereas the percentages rate of referral for dermatological evaluation varied from 44% to 99%. Melanoma cases referred to dermatologist ranges from 67% to 99%. This preliminary analysis on pre-training questionnaire mainly showed a lack of knowledge of the two major points of melanoma diagnosis (EFG) and management (Breslow thickness), as well as a low rate of participants. We will compare the proportions of correct answers to the questionnaires before and after the course once available. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup

Author

Bruno, William, Pastorino, Lorenza, Ghiorzo, Paola, Andreotti, Virginia, Martinuzzi, Claudia, Menin, Chiara, Elefanti, Lisa, Stagni, Camilla, Vecchiato, Antonella, Rodolfo, Monica, Maurichi, Andrea, Manoukian, Siranoush, De Giorgi, Vincenzo, Savarese, Imma, Gensini, Francesca, Borgognoni, Lorenzo, Testori, Alessandro, Spadola, Giuseppe, Mandalà, Mario, Imberti, Gianlorenzo, Savoia, Paola, Astrua, Chiara, Ronco, Anna Maria, Farnetti, Alessandra, Tibiletti, Maria Grazia, Lombardo, Maurizio, Palmieri, Giuseppe, Ayala, Fabrizio, Ascierto, Paolo, Ghigliotti, Giovanni, Muggianu, Marisa, Spagnolo, Francesco, Picasso, Virginia, Tanda, Enrica Teresa, Queirolo, Paola, and Bianchi-Scarrà, Giovanna

Published
2016
Full Text
View/download PDF

9. The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.

Author

Patuzzo, Roberto, Mattavelli, Ilaria, Gallino, Gianfranco, Galeone, Carlotta, Valeri, Barbara, Mocellin, Simone, Del Fiore, Paolo, Ribero, Simone, Mandalà, Mario, Tauceri, Francesca, Lombardo, Maurizio, and Maurichi, Andrea

Subjects
CUTANEOUS malignant melanoma, PROPORTIONAL hazards models, PROGNOSIS
Abstract

Background: This study aimed to improve the understanding of the prognostic value of tumor mitotic rate (TMR) in cutaneous melanoma and assessed its significance as a predictor for overall, melanoma‐specific, and recurrence‐free survival. Patients and Methods: This is a retrospective multicenter Italian cohort study of 13,016 patients diagnosed with and treated for invasive primary melanoma between 2005 and 2020 with median follow‐up of 5.5 years. The survival probability was assessed by Kaplan–Meier method, hazard ratios (HRs), and corresponding 95% confidence interval (CI) of all‐cause mortality and recurrence/death by multivariable Cox proportional hazards models. Results: Higher dermal mitoses number was associated with decreased overall survival. Among patients with TMR 0/mm2, 1/mm2, 2/mm2–3/mm2, 4/mm2–10/mm2, and >10/mm2, 5‐year overall survival (OS) was 97.3%, 93.6%, 88.3%, 73.0%, and 60.9%, respectively. In multivariate analyses, compared to TMR of 0/mm2, HRs for all‐cause mortality were 1.35 (95% CI, 1.08–1.68), 1.70 (95% CI, 1.40–2.07), 2.04 (95% CI, 1.67–2.49), and 2.39 (95% CI, 1.90–3.00) for 1 mitoses/mm2, 2 mitoses/mm2–3 mitoses/mm2, 4 mitoses/mm2–10 mitoses/mm2, and >10 mitoses/mm2, respectively. A similar increase in risks was observed in melanoma‐specific survival (MSS) and recurrence‐free survival (RFS). The HRs for MSS and RFS for the highest compared to the lowest TMR category were 3.01 (95% CI, 2.20–4.11) and 2.26 (95% CI, 1.88–2.73), respectively. Sentinel lymph‐node biopsy positivity was significantly associated with TMR increase even with adjustment for several potential confounders. Conclusions: A clear association was demonstrated between an increasing TMR and decreased OS, MSS, and RFS, suggesting a reconsideration of TMR prognostic role for future inclusion in the melanoma staging system. Plain Language Summary: The 8th American Joint Committee on Cancer for melanoma staging removed tumor mitotic rate (TMR) from the staging criteria for T1 melanomas, giving way to ulceration and tumor thickness as stronger prognostic predictors.However, it is still recommended that TMR should be assessed and recorded in all primary invasive melanomas.In a large retrospective multicenter study on primary invasive melanomas, we investigated the prognostic value of TMR to assess its significance as survival predictor.Our results showed a clear association between increasing TMR and decreased patients' survival, suggesting that TMR should be considered for inclusion in the melanoma staging system. Increasing tumor mitotic rate (TMR) is clearly associated with decreased overall, melanoma‐specific, and recurrence‐free survival. Our results suggest that the prognostic role of TMR should be reconsidered, and dermal mitotic rate should be assessed and recorded for all primary melanomas. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVID observational study

Author

Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iris, Bianchi, Luca, Peris, Ketty, PSO-BIO-COVID study group, Balestri R, Bernardini N, Belloni Fortini A, Burlando M, Caldarola G, Campione E, Cattaneo A, Dapavo P, Dastoli S, De Simone C, Di Nuzzo S, Diotallevi F, Fierro MT, Franchi C, Esposito M, Foti C, Gambini DM, Gambardella A, Girolomoni G, Giunta A, Guarneri C, Gualdi G, Hansel K, Megna M, Mugheddu C, Musumeci ML, Patrizi A, Pellacani G, Richetta AG, Rosi E, Sacchelli L, Tiberio R, Tilotta G, Trovato E, Venturini M, Vezzoni R, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo', S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iri, Bianchi, Luca, Peris, Ketty, PSO-BIO-COVID study, Group, Balestri, R, Bernardini, N, Belloni Fortini, A, Burlando, M, Caldarola, G, Campione, E, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, Mt, Franchi, C, Esposito, M, Foti, C, Gambini, Dm, Gambardella, A, Girolomoni, G, Giunta, A, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, Ml, Patrizi, A, Pellacani, G, Richetta, Ag, Rosi, E, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Venturini, M, Vezzoni, R, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A.V., Potenza C., Conti A., Parodi A., Piaserico S., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Rossi M.T., Bongiorno M.R., Feliciani C., Rubegni P., Amerio P., Fargnoli M.C., Pigatto P., Savoia P., Nistico S.P., Giustini S., Carugno A., Cannavo' S.P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., and Peris K.

Subjects
0301 basic medicine, Male, Clinical Biochemistry, Disease, Cohort Studies, 0302 clinical medicine, Drug Discovery, Receptors, 80 and over, Medicine, Aged, 80 and over, education.field_of_study, Incidence (epidemiology), Incidence, Interleukin-17, psoriasis, Middle Aged, dermatology, sars-CoV-2, Italy, biological therapy, 030220 oncology & carcinogenesis, Cohort, Biological Product, COVID-19, Female, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Adult, Aged, Biological Products, Biological Therapy, Chronic Disease, Humans, Pandemics, Psoriasis, Receptors, Interleukin, Risk Assessment, Tumor Necrosis Factor-alpha, Young Adult, Cohort study, Human, medicine.medical_specialty, Population, 03 medical and health sciences, Settore MED/35, Internal medicine, education, Pharmacology, Psoriasi, Pandemic, business.industry, Biological product, Interleukin, medicine.disease, Clinical trial, 030104 developmental biology, SARS-CoV-2, Cohort Studie, business
Abstract

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort twenty-six patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. 125 of 12807 patients (1.0%) with exposure to a patient with COVID-19 under quarantine or active health surveillance, were reported. Conclusion The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen "cytokine storm" of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.

Published
2021

12. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

Author

Chiricozzi, Andrea, Talamonti, Marina, De Simone, Clara, Galluzzo, Marco, Gori, Niccolò, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iris, Lombardo, Maurizio, Feliciani, Claudio, Di Nardo, Lucia, Guarneri, Fabrizio, Peris, Ketty, Caldarola, Giacomo, Silvaggio, Dionisio, Dattola, Annunziata, Napolitano, Maddalena, Ferrucci, Silvia Mariel, Dal Bello, Giacomo, Bianchelli, Tommaso, Rovati, Chiara, Pigliacelli, Flavia, Ortoncelli, Michela, Hansel, Katharina, Calabrese, Giulia, Loi, Camilla, Iannone, Michela, Veronese, Federica, Romita, Paolo, Tronconi, Greta, Caroppo, Francesca, Tilotta, Giovanna, Sernicola, Alvise, Esposito, Maria, Raponi, Francesca, Gualdi, Giulio, Rech, Giulia, Musumeci, Maria Letizia, Nisticò, Steven Paul, Campitiello, Alessio, Bonzano, Laura, Piras, Viviana, Chiricozzi, A., Talamonti, M., De Simone, C., Galluzzo, M., Gori, N., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Di Nardo, L., Guarneri, F., Peris, K., Caldarola, G., Silvaggio, D., Dattola, A., Napolitano, M., Ferrucci, S. M., Dal Bello, G., Bianchelli, T., Rovati, C., Pigliacelli, F., Ortoncelli, M., Hansel, K., Calabrese, G., Loi, C., Iannone, M., Veronese, F., Romita, P., Tronconi, G., Caroppo, F., Tilotta, G., Sernicola, A., Esposito, M., Raponi, F., Gualdi, G., Rech, G., Musumeci, M. L., Nistico, S. P., Campitiello, A., Bonzano, L., Piras, V., Chiricozzi, Andrea, Talamonti, Marina, De Simone, Clara, Galluzzo, Marco, Gori, Niccolò, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iri, Lombardo, Maurizio, Feliciani, Claudio, Di Nardo, Lucia, Guarneri, Fabrizio, Peris, Ketty, Caldarola, Giacomo, Silvaggio, Dionisio, Dattola, Annunziata, Napolitano, Maddalena, Ferrucci, Silvia Mariel, Dal Bello, Giacomo, Bianchelli, Tommaso, Rovati, Chiara, Pigliacelli, Flavia, Ortoncelli, Michela, Hansel, Katharina, Calabrese, Giulia, Loi, Camilla, Iannone, Michela, Veronese, Federica, Romita, Paolo, Tronconi, Greta, Caroppo, Francesca, Tilotta, Giovanna, Sernicola, Alvise, Esposito, Maria, Raponi, Francesca, Gualdi, Giulio, Rech, Giulia, Musumeci, Maria Letizia, Nisticò, Steven Paul, Campitiello, Alessio, Bonzano, Laura, Piras, Viviana, Chiricozzi, A, Talamonti, M, De Simone, C, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di Nardo, L, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, S, Dal Bello, G, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, M, Nistico, S, Campitiello, A, Bonzano, L, and Piras, V

Subjects
Registrie, 0301 basic medicine, Dermatitis, Systemic therapy, 0302 clinical medicine, Pandemic, Immunology and Allergy, Medicine, Registries, atopic dermatitis, COVID, SARS‐ CoV, treatment, SARS-CoV, Atopic dermatitis, Dupilumab, Italy, Original Article, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Human, atopic dermatiti, Adult, medicine.medical_specialty, Teledermatology, SARS‐CoV, atopic dermatitis, treatment, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunology, Communicable Disease Control, Humans, Pandemics, SARS-CoV-2, COVID-19, Dermatitis, Atopic, Atopic, 03 medical and health sciences, Settore MED/35, Disease severity, Internal medicine, business.industry, medicine.disease, 030104 developmental biology, 030228 respiratory system, atopic dermatitis, COVID, SARS-CoV, business
Abstract

Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID‐19) pandemic. Methods A national registry, named DA‐COVID‐19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID‐19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID‐19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician‐ and patient‐reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS‐CoV‐2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS‐CoV‐2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID‐related death occurred. Conclusions Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab‐treated patients., Among 1831 studied AD patients, 86.1% were treated with dupilumab. Patients continuing therapy experienced a marked reduction of disease severity during pandemic. The causes of treatment interruption included: fear of increased susceptibility to SARS‐CoV‐2 infection (24.8%), occurrence of comorbidities (5.9%), age above 60 years (5.2%), SARS‐CoV‐2 infection (2.8%), close contact with SARS‐CoV‐2‐positive subject (2.4%), other reasons, for example, inability to maintain drug supply, non‐medical/unspecified causes (58.7%).

Published
2021

14. Clinical genetic testing for familial melanoma in Italy: A cooperative study

Author

Bruno, William, Ghiorzo, Paola, Battistuzzi, Linda, Ascierto, Paolo A., Barile, Monica, Gargiulo, Sara, Gensini, Francesca, Gliori, Sara, Guida, Michele, Lombardo, Maurizio, Manoukian, Siranoush, Menin, Chiara, Nasti, Sabina, Origone, Paola, Pasini, Barbara, Pastorino, Lorenza, Peissel, Bernard, Pizzichetta, Maria Antonietta, Queirolo, Paola, Rodolfo, Monica, Romanini, Antonella, Scaini, Maria Chiara, Testori, Alessandro, Tibiletti, Maria Grazia, Turchetti, Daniela, Leachman, Sancy A., and Bianchi Scarrà, Giovanna

Published
2009
Full Text
View/download PDF

15. Mental Health Consequences of the COVID-19 Pandemic Long-Term Exposure in Italian Dermatologists

Author

Ciuluvica, Cristina, primary, Gualdi, Giulio, additional, Dal Canton, Marco, additional, Fantini, Fabrizio, additional, Paradisi, Andrea, additional, Sbano, Paolo, additional, Simonacci, Marco, additional, Dusi, Daniele, additional, Vezzoni, Gian Marco, additional, D’Acunto, Carmine, additional, Lombardo, Maurizio, additional, Zanchi, Malvina, additional, Alfredo, Zucchi, additional, Eisendle, Klaus, additional, Prignano, Francesca, additional, and Amerio, Paolo, additional

Published
2021
Full Text
View/download PDF

16. The Role Of Sentinel Node Tumor Burden In Modeling The Prognosis Of Melanoma Patients With Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup Study (N=2,086)

Author

Tropea, Saveria, primary, Fiore, Paolo Del, additional, Maurichi, Andrea, additional, Patuzzo, Roberto, additional, Santinami, Mario, additional, Ribero, Simone, additional, Quaglino, Pietro, additional, Caliendo, Virginia, additional, Borgognoni, Lorenzo, additional, Sestini, Serena, additional, Giudice, Giuseppe, additional, Nacchiero, Eleonora, additional, Caracò, Corrado, additional, Cordova, Adriana, additional, Solari, Nicola, additional, Piazzalunga, Dario, additional, Tauceri, Francesca, additional, Carcoforo, Paolo, additional, Lombardo, Maurizio, additional, Cavallari, Sara, additional, and Mocellin, Simone, additional

Published
2021
Full Text
View/download PDF

17. Pathology of Immunotherapy-induced Responses in Cutaneous Melanoma: Current Evidences and Future Perspectives

Author

Indini, Alice, Lombardo, Maurizio, Sidoni, Angelo, Gianatti, Andrea, Mandalà, Mario, and Massi, Daniela

Abstract

Over the last years, immune checkpoint inhibitors (ICIs) have demonstrated remarkable anti-tumor activity and beneficial effects in patients with early and advanced melanoma. However, ICIs provide clinical benefit only in a minority of patients due to primary and/or acquired resistance mechanisms. Immunotherapy resistance is a complex phenomenon relying on genetic and epigenetic factors, which ultimately influence the interplay between cancer cells and the tumor microenvironment. Information is accumulating on the cellular and molecular mechanisms underlying the production of resistance and the resulting diminished therapeutic efficacy. In addition, current knowledge on predictors of response and toxicity to immunotherapy and on biomarkers that reliably identify resistant patients is in progress. In this review, we will focus on the tumor microenvironment changes induced by ICIs in melanoma, summarizing the available evidence of clinical trials in the neoadjuvant and metastatic setting. We will also overview the role of potential biomarkers in predicting disease response to ICIs, providing insight into current and future research in this field.

Published
2023
Full Text
View/download PDF

18. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry Running title: AD management during COVID-19 pandemic

Author

Chiricozzi, Andrea, primary, Talamonti, Marina, additional, Simone, Clara De, additional, Galluzzo, Marco, additional, Gori, Niccolò, additional, Fabbrocini, Gabriella, additional, Marzano, Angelo Valerio, additional, Girolomoni, Giampiero, additional, Offidani, Annamaria, additional, Rossi, Maria Teresa, additional, Bianchi, Luca, additional, Cristaudo, Antonio, additional, Fierro, Maria Teresa, additional, Stingeni, Luca, additional, Pellacani, Giovanni, additional, Argenziano, Giuseppe, additional, Patrizi, Annalisa, additional, Pigatto, Paolo, additional, Romanelli, Marco, additional, Savoia, Paola, additional, Rubegni, Pietro, additional, Foti, Caterina, additional, Milanesi, Nicola, additional, Fortina, Anna Belloni, additional, Bongiorno, Maria Rita, additional, Grieco, Teresa, additional, Nuzzo, Sergio Di, additional, Fargnoli, Maria Concetta, additional, Carugno, Andrea, additional, Motolese, Alberico, additional, Rongioletti, Franco, additional, Amerio, Paolo, additional, Balestri, Riccardo, additional, Potenza, Concetta, additional, Micali, Giuseppe, additional, Patruno, Cataldo, additional, Zalaudek, Iris, additional, Lombardo, Maurizio, additional, Feliciani, Claudio, additional, Nardo, Lucia Di, additional, Guarneri, Fabrizio, additional, Peris, Ketty, additional, and Da-, Md ;, additional

Published
2021
Full Text
View/download PDF

19. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry

Author

Chiricozzi, Andrea, primary, Talamonti, Marina, additional, Simone, Clara De, additional, Galluzzo, Marco, additional, Gori, Niccolò, additional, Fabbrocini, Gabriella, additional, Marzano, Angelo, additional, Girolomoni, Giampiero, additional, Offidani, Anna Maria, additional, Rossi, Maria Teresa, additional, Bianchi, Luca, additional, Cristaudo, Antonio, additional, Fierro, Maria Teresa, additional, Stingeni, Luca, additional, Pellacani, Giovanni, additional, Argenziano, Giovanni, additional, Patrizi, Annalisa, additional, Pigatto, Paolo, additional, Romanelli, Marco, additional, Savoia, Paola, additional, Rubegni, Pietro, additional, Foti, Caterina, additional, Milanesi, Nicola, additional, Fortina, Anna Belloni, additional, Bongiorno, Maria Rita, additional, Grieco, Teresa, additional, Nuzzo, Sergio Di, additional, Fargnoli, Maria Concetta, additional, Carugno, Andrea, additional, Motolese, Alberico, additional, Rongioletti, Franco, additional, Amerio, Paolo, additional, Balestri, Riccardo, additional, Potenza, Concetta, additional, Micali, Giuseppe, additional, Patruno, Cataldo, additional, Zalaudek, Iris, additional, Lombardo, Maurizio, additional, Feliciani, Claudio, additional, Guarneri, Fabrizio, additional, and Peris, Ketty, additional

Published
2020
Full Text
View/download PDF

27. The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086)

Author

Saveria, Tropea, Paolo, Del Fiore, Andrea, Maurichi, Roberto, Patuzzo, Mario, Santinami, Simone, Ribero, Pietro, Quaglino, Virginia, Caliendo, Lorenzo, Borgognoni, Serena, Sestini, Giuseppe, Giudice, Eleonora, Nacchiero, Corrado, Caracò, Adriana, Cordova, Nicola, Solari, Dario, Piazzalunga, Francesca, Tauceri, Paolo, Carcoforo, Maurizio, Lombardo, Sara, Cavallari, Simone, Mocellin, Carlo, Riberti, Tropea, Saveria, Del Fiore, Paolo, Maurichi, Andrea, Patuzzo, Roberto, Santinami, Mario, Ribero, Simone, Quaglino, Pietro, Caliendo, Virginia, Borgognoni, Lorenzo, Sestini, Serena, Giudice, Giuseppe, Nacchiero, Eleonora, Caracò, Corrado, Cordova, Adriana, Solari, Nicola, Piazzalunga, Dario, Tauceri, Francesca, Carcoforo, Paolo, Lombardo, Maurizio, Cavallari, Sara, and Mocellin, Simone

Subjects
Oncology, Male, Treatment of cutaneous melanoma, medicine.medical_specialty, Completion lymph node dissection, Skin Neoplasms, CLND, Melanoma, Metastatic melanoma in the sentinel nodes, Nomogram, Overall survival, Prognostic factors, Risk stratification, Tumor burden, Humans, Lymph Node Excision, Lymphatic Metastasis, Prognosis, Retrospective Studies, Sentinel Lymph Node Biopsy, Tumor Burden, Lymphadenopathy, Sentinel Lymph Node, Settore MED/19 - Chirurgia Plastica, Internal medicine, Biopsy, medicine, medicine.diagnostic_test, business.industry, Sentinel node, medicine.disease, business
Abstract

Background: The management of melanoma patients with metastatic sentinel nodes (SN) is evolving based on the results of trials questioning the impact of completion lymph node dissection (CLND) and demonstrating the efficacy of new adjuvant treatments. In this landscape, new prognostic tools for fine risk stratification are eagerly sought to optimize the therapeutic path of these patients. Methods: A retrospective cohort of 2,086 patients treated with CLND after a positive SN biopsy in thirteen Italian Melanoma Centers was reviewed. Overall survival (OS) was the outcome of interest; included independent variables were the following: age, gender, primary melanoma site, Breslow thickness, ulceration, sentinel node tumor burden (SNTB), number of positive SN, non-sentinel lymph nodes (NSN) status. Univariate and multivariate survival analyses were performed using the Cox proportional hazard regression model. Results: The 3-year, 5-year and 10-year OS rates were 79 %, 70% and 54%, respectively. At univariate analysis, all variables, except for primary melanoma body site, were found to be statistically significant prognostic factors. Multivariate Cox regression analysis indicated that older age (P< 0.0001), male gender (P= 0.04), increasing Breslow thickness (P

Published
2022

28. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry.

Author

Chiricozzi A, Talamonti M, De Simone C, Galluzzo M, Gori N, Fabbrocini G, Marzano AV, Girolomoni G, Offidani A, Rossi MT, Bianchi L, Cristaudo A, Fierro MT, Stingeni L, Pellacani G, Argenziano G, Patrizi A, Pigatto P, Romanelli M, Savoia P, Rubegni P, Foti C, Milanesi N, Belloni Fortina A, Bongiorno MR, Grieco T, Di Nuzzo S, Fargnoli MC, Carugno A, Motolese A, Rongioletti F, Amerio P, Balestri R, Potenza C, Micali G, Patruno C, Zalaudek I, Lombardo M, Feliciani C, Di Nardo L, Guarneri F, and Peris K

Subjects
Adult, Communicable Disease Control, Humans, Italy epidemiology, Pandemics, Registries, SARS-CoV-2, COVID-19, Dermatitis, Atopic drug therapy, Dermatitis, Atopic epidemiology
Abstract

Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic., Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity., Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred., Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients., (© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)

Published
2021
Full Text
View/download PDF

29. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study.

Author

Talamonti M, Galluzzo M, Chiricozzi A, Quaglino P, Fabbrocini G, Gisondi P, Marzano AV, Potenza C, Conti A, Parodi A, Piaserico S, Bardazzi F, Argenziano G, Rongioletti F, Stingeni L, Micali G, Loconsole F, Rossi MT, Bongiorno MR, Feliciani C, Rubegni P, Amerio P, Fargnoli MC, Pigatto P, Savoia P, Nisticò SP, Giustini S, Carugno A, Cannavo' SP, Rech G, Prignano F, Offidani A, Lombardo M, Zalaudek I, Bianchi L, Peris K, Balestri R, Bernardini N, Belloni Fortini A, Burlando M, Caldarola G, Campione E, Cattaneo A, Dapavo P, Dastoli S, De Simone C, Di Nuzzo S, Diotallevi F, Fierro MT, Franchi C, Esposito M, Foti C, Gambini DM, Gambardella A, Girolomoni G, Giunta A, Guarneri C, Gualdi G, Hansel K, Megna M, Mugheddu C, Musumeci ML, Patrizi A, Pellacani G, Richetta AG, Rosi E, Sacchelli L, Tiberio R, Tilotta G, Trovato E, Venturini M, and Vezzoni R

Subjects
Adult, Aged, Aged, 80 and over, Biological Products pharmacology, COVID-19 diagnosis, Chronic Disease, Cohort Studies, Female, Humans, Incidence, Interleukin-17 antagonists & inhibitors, Italy epidemiology, Male, Middle Aged, Pandemics, Psoriasis diagnosis, Psoriasis epidemiology, Receptors, Interleukin antagonists & inhibitors, Risk Assessment methods, Tumor Necrosis Factor-alpha antagonists & inhibitors, Young Adult, Biological Products therapeutic use, Biological Therapy methods, COVID-19 epidemiology, Psoriasis drug therapy
Abstract

Background : The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods : Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. Results : A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort 26 patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. Conclusion : The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen 'cytokine storm' of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results